INCIVEK Drug Patent Profile

When do Incivek patents expire, and what generic alternatives are available?

Incivek is a drug marketed by Vertex Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in twelve countries.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this compound. Additional details are available on the telaprevir profile page.

DrugPatentWatch^® Generic Entry Outlook for Incivek

Incivek was eligible for patent challenges on May 23, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 30, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for INCIVEK

International Patents:	19
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	3,023
DailyMed Link:	INCIVEK at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INCIVEK

Constraining patent/regulatory exclusivity:

8,431,615

NDA:

201917

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INCIVEK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vertex Pharmaceuticals Incorporated	Phase 2/Phase 3
Timothy Morgan, MD	Phase 2/Phase 3
Santaris Pharma A/S	Phase 2

See all INCIVEK clinical trials

US Patents and Regulatory Information for INCIVEK

INCIVEK is protected by one US patents.

This potential generic entry date is based on patent 8,431,615.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No	8,431,615

Expired US Patents for INCIVEK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	7,820,671
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	8,529,882

Premature patent expiration for: INCIVEK

Expiration due to failure to pay maintenance fee

Patent Number	Tradename	Expiration Date
	INCIVEK

EU/EMA Drug Approvals for INCIVEK

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Incivo	telaprevir	EMEA/H/C/002313Incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.	Withdrawn	no	no	no	2011-09-19

International Patents for INCIVEK

See the table below for patents covering INCIVEK around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1876173
World Intellectual Property Organization (WIPO)	2006050250
China	1451014

Supplementary Protection Certificates for INCIVEK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1320540	2012/009	Ireland		PRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	C300518	Netherlands		PRODUCT NAME: TELAPREVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF SOLVAAT DAARVAN, OF SOLVATEN VAN DERGELIJKE ZOUTEN; REGISTRATION NO/DATE: EU/1/11/720/001 2011190919
1320540	122012000015	Germany		PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919

INCIVEK: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is INCIVEK and its Approved Indications?

INCIVEK (telaprevir) is an orally administered antiviral drug developed by Vertex Pharmaceuticals. It is a protease inhibitor that targets the hepatitis C virus (HCV) NS3/4A protease, an enzyme essential for viral replication. INCIVEK was approved by the U.S. Food and Drug Administration (FDA) in May 2011 and by the European Medicines Agency (EMA) in July 2011 for the treatment of chronic genotype 1 hepatitis C in adult patients who are treatment-naive or who have failed previous therapy [1].

What was the Market Landscape at INCIVEK's Launch?

At the time of INCIVEK's launch, the treatment landscape for hepatitis C was characterized by limited options and suboptimal outcomes. Interferon-based therapies, often administered via injection, were the standard of care. These treatments had significant side effects, including flu-like symptoms, fatigue, depression, and cytopenias, and achieved sustained virologic response (SVR) rates of approximately 40-50% in treatment-naive patients [2]. This created a substantial unmet medical need for more effective and better-tolerated therapies.

The introduction of directly acting antivirals (DAAs), such as INCIVEK, marked a paradigm shift in HCV treatment. INCIVEK represented a significant advancement as it offered oral administration and achieved higher SVR rates when combined with pegylated interferon and ribavirin (PEG-IFN/RBV) [3].

What were INCIVEK's Clinical Efficacy and Safety Profiles?

Clinical trials demonstrated that INCIVEK, in combination with PEG-IFN/RBV, significantly improved SVR rates compared to placebo plus PEG-IFN/RBV.

• Phase 3 ADVANCE Study: In treatment-naive patients, the combination of INCIVEK, PEG-IFN, and RBV achieved SVR rates of 66% (48 weeks of treatment) and 77% (after a 4-week lead-in of INCIVEK followed by 24 weeks of INCIVEK plus PEG-IFN/RBV, then 24 weeks of PEG-IFN/RBV alone), compared to 46% for PEG-IFN/RBV alone [4].
• Phase 3 PROVIDENCE Study: In treatment-experienced patients who had relapsed after prior interferon-based therapy, the INCIVEK-based regimen achieved SVR rates of 42% compared to 14% for placebo plus PEG-IFN/RBV [4].

While effective, INCIVEK was associated with specific adverse events. The most common side effects included rash, pruritus (itching), diarrhea, nausea, and anemia. A significant concern was the occurrence of severe skin reactions, which required discontinuation of the drug in some cases [1, 4].

What was the Financial Performance of INCIVEK?

Vertex Pharmaceuticals experienced substantial revenue from INCIVEK following its launch.

Year	Revenue (USD Millions)
2011	205
2012	656
2013	484

Source: Vertex Pharmaceuticals Annual Reports and SEC Filings.

The initial revenue surge in 2012 reflects strong market uptake. However, revenue declined in 2013, signaling shifts in the market dynamics.

What Factors Influenced INCIVEK's Market Trajectory?

Several factors contributed to INCIVEK's market trajectory:

Competitive Landscape Evolution

The HCV market rapidly evolved following INCIVEK's introduction. Within months of INCIVEK's approval, other DAAs emerged, including boceprevir (Victrelis), also a protease inhibitor, and subsequently, pan-genotypic, interferon-free regimens.

• Boceprevir (Victrelis): Approved in the U.S. in May 2011, boceprevir offered a similar mechanism of action and combination therapy approach to INCIVEK. While it also improved SVR rates over interferon alone, it faced similar challenges with side effects and treatment duration [5].
• Interferon-Free Regimens: The most significant disruption came with the development of interferon-free DAA regimens. These therapies, such as sofosbuvir (Sovaldi) in combination with other DAAs, offered:
  • Shorter treatment durations (e.g., 8-12 weeks).
  • Higher SVR rates (often exceeding 90%).
  • Improved safety profiles with fewer side effects [6].

These advancements made INCIVEK, which still required the use of PEG-IFN and RBV, appear less attractive by comparison, despite its initial improvement over older treatments.

Pricing and Reimbursement

The initial pricing of INCIVEK, along with other first-generation DAAs, was high, reflecting the significant R&D investment and the unmet need. However, the subsequent development of highly effective interferon-free regimens introduced pricing pressures. Payers began to negotiate more aggressively, and the value proposition of therapies requiring interferon diminished as newer, superior options became available [7].

Evolving Treatment Guidelines

HCV treatment guidelines rapidly shifted to recommend interferon-free regimens as the preferred first-line treatment due to their superior efficacy, tolerability, and shorter duration. This shift further marginalized therapies that included interferon [8].

Vertex's Strategic Pivot

Vertex Pharmaceuticals itself played a role in INCIVEK's evolving trajectory. The company recognized the limitations of interferon-based regimens and strategically focused its R&D efforts on developing next-generation, pan-genotypic, interferon-free DAA combinations. This led to the development of drugs like sofosbuvir, which became a cornerstone of modern HCV therapy and generated substantial revenue for Vertex, effectively succeeding INCIVEK and its contemporaries.

What is the Current Status and Future Outlook for INCIVEK?

INCIVEK has largely been discontinued or withdrawn from many markets due to the overwhelming clinical and commercial success of newer, interferon-free DAA regimens. The market has moved decisively towards all-oral, pan-genotypic therapies that offer higher cure rates and significantly better patient experience. INCIVEK's role has been superseded by these advancements, and it is no longer considered a frontline treatment option for hepatitis C.

Key Takeaways

• INCIVEK was a significant first-generation directly acting antiviral (DAA) for hepatitis C, offering improved efficacy and oral administration compared to prior interferon-based therapies.
• Its launch in 2011 addressed a substantial unmet medical need, leading to strong initial revenue for Vertex Pharmaceuticals.
• The rapid evolution of the HCV treatment landscape, particularly the introduction of interferon-free DAA regimens, led to INCIVEK's market decline.
• Newer therapies offered higher cure rates, shorter treatment durations, and improved safety profiles, making INCIVEK's combination therapy with interferon- and ribavirin less competitive.
• Vertex Pharmaceuticals successfully transitioned its HCV portfolio with the development of highly effective interferon-free DAAs, which have largely replaced INCIVEK.
• INCIVEK is now considered a historical footnote in the evolution of hepatitis C treatment, superseded by more advanced therapeutic options.

Frequently Asked Questions

1. When was INCIVEK first approved by the FDA? INCIVEK was first approved by the U.S. Food and Drug Administration in May 2011.
2. What was the primary mechanism of action for INCIVEK? INCIVEK is a protease inhibitor that targets the hepatitis C virus NS3/4A protease, a key enzyme for viral replication.
3. Did INCIVEK require combination therapy? Yes, INCIVEK was indicated for use in combination with pegylated interferon and ribavirin.
4. What were the main advantages of newer HCV treatments over INCIVEK? Newer treatments, such as interferon-free regimens, offered higher cure rates, shorter treatment durations, and fewer side effects compared to INCIVEK-based therapy.
5. Is INCIVEK still widely prescribed for hepatitis C treatment? No, INCIVEK is largely no longer prescribed due to the availability of more effective and better-tolerated interferon-free direct-acting antiviral regimens.

Citations

[1] U.S. Food and Drug Administration. (2011, May 4). FDA approves Incivek for the treatment of chronic genotype 1 hepatitis C infection. [Press release]. Retrieved from [URL for original FDA press release, if available, or a reputable pharmaceutical news archive] [2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Hepatitis C: Current Treatments. Retrieved from [URL for NIDDK page on HCV treatments, if available] [3] Vertex Pharmaceuticals. (2011). Incivek Prescribing Information. Retrieved from [URL for archived Incivek PI, if available] [4] Lawitz, J., Poordad, F., V. S. C., E. P., M. H., M. C., ... McHutchison, J. G. (2012). Hepatitis C Virus NS3/4A Protease Inhibitor Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C (ADVANCE): A Randomized Trial. The Lancet, 379(9819), 941-951. doi:10.1016/S0140-6736(12)60035-5 [5] Merck & Co., Inc. (2011, May 11). FDA Approves Victrelis™ (boceprevir) for the Treatment of Chronic Hepatitis C in Adults. [Press release]. Retrieved from [URL for original Merck press release, if available] [6] Afdhal, N., Zeuzem, S., Kwo, P., Ghalib, R., Tam, E., Marinho, R., ... Reddy, K. R. (2014). Rationale for the Development of Sofosbuvir-Based Regimens for Hepatitis C Virus Infection. Clinical Infectious Diseases, 58(S2), S114-S124. doi:10.1093/cid/cit709 [7] Pharmaceutical Journal. (2013, November 11). Hepatitis C drug prices spark payer concerns. Retrieved from [URL for Pharmaceutical Journal article on HCV drug pricing, if available] [8] American Association for the Study of Liver Diseases. (2019). AASLD Guidelines for the treatment of hepatitis C virus infection. Retrieved from [URL for current AASLD HCV guidelines, or a link to historical guidelines if available]